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MicroRNAs (miRNAs) play an important role in regulating gene expression in health and 
disease but their role in modifying disease expression in ADPKD remains uncertain. In this 
study, we profiled human urinary exosome miRNA by global small RNA-sequencing in an 
initial discovery cohort of ADPKD patients with early (eGFR >60ml/min/1.73m2, n=7) and 
late (eGFR <60ml/min/1.73m2, n=9) disease and compared their differential expression 
with age and sex matched healthy controls (n=6). Two candidate miRNA families 
identified (miR-192/miR-194-2 and miR-30) were selected for confirmatory testing in a 
validation cohort (n=60) by quantitative PCR. We confirmed that miR-192-5p, miR-194-
5p, miR-30a-5p, miR-30d-5p and miR-30e-5p were significantly downregulated in human 
urine exosomes, in murine Pkd1 cystic kidneys and in human PKD1 cystic kidney tissue. 
All 5 miRNAs showed significant correlations with baseline eGFR and ultrasound-
determined mean kidney length (MKL) and improved the diagnostic performance (AUC) 
of MKL for the rate of disease progression. Finally, inverse correlations of these two 
miRNA families with increased expression in their predicted target genes in human PKD1 
cystic tissue identified dysregulated pathways and transcriptional networks including novel 
interactions between miR-194-5p and two potentially relevant candidate genes, PIK3R1 
and ANO1. Our results identify a subset of urinary exosomal miRNAs that could serve as 
novel biomarkers of disease progression and suggest new therapeutic targets in ADPKD.  
 
Keywords: ADPKD, microRNA, urine exosomes, PKD1  
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INTRODUCTION 
Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common 
human monogenic diseases with an estimated prevalence of 1:1000 to 1:2500. It is 
characterized by the progressive development and enlargement of focal kidney cysts 
typically resulting in end-stage renal disease (ESRD) by the fifth decade 1. Mutations of 
PKD1 and PKD2 account for ~85% and ~15% of ADPKD, respectively and together, they 
account for ~10% of prevalent patients with ESRD 1. Polycystin-1 (PC1) and polycystin-2 
(PC2), the proteins encoded by PKD1 and PKD2, function as a receptor-ion channel 
complex that maintains normal tubular structure and function through multiple signaling 
pathways 2. The renal phenotype of ADPKD is however highly variable and this variability 
is only partly accounted for by locus and allelic factors. These differences are particularly 
exemplified by striking intra-familial variability in the age of onset of ESRD observed in 
some families 3 4. The modifying role of environmental factors acting through somatic 
mutations, epigenetic changes and non-coding regulatory RNAs are only just being 
explored.  
 
MicroRNAs (miRNAs) are ~22nt non-coding regulatory RNAs that function as inhibitors 
of post-transcriptional gene expression in plants and animals 5. Several lines of evidence 
have revealed the role of miRNAs in experimental models of PKD6-16. First, differentially 
expressed miRNAs have been identified in animal models6-9. Second, the miR-17~92 
miRNA cluster is upregulated in the kidney of several models and overexpression of miR-
17~92 miRNA cluster leads to cyst formation in mice12. Specifically, miR-17 represses 
PKD1, PKD2 and PPARA10-12, 16, whereas miR-17~92 inhibits PKHD1 through the 
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transcriptional factor HNF1B 12. Third, several other miRNAs have been implicated in the 
pathogenesis of PKD, including: miR-15a 7, miR-21 13 and miR-200 miRNA family 
members 15. However, there have been few consistent findings between different models 
and importantly, a relative lack of confirmatory human studies 17.  
 
In this study, we have taken a systems biology approach to discover dysregulated miRNAs 
in human ADPKD. Starting with human urinary exosomes, we first identified differentially 
expressed miRNA between ADPKD patients and healthy controls by global miRNA-
sequencing. Members of two kidney-enriched miRNA families (miR-192/miR-194-2 and 
miR-30) were then validated in a larger patient cohort and in Pkd1 mouse kidneys of 
different ages. We then confirmed these findings in an independent global miRNA 
microarray analysis performed on normal and PKD1 human cystic tissue. By integrating 
these miRNAs with previously identified dysregulated genes/gene pathways in ADPKD18, 
we found a significant inverse correlation between expression of these down-regulated 
miRNAs and their predicted target genes including previously unreported interactions 
between miR-194-5p and two candidate genes, PIK3R1 and ANO1. The use of global 
miRNA profiling has allowed us to identify a subset of urinary exosomal miRNAs as 




Differential expression of a subset of miRNAs in ADPKD urine exosomes by global 
miRNA sequencing 
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Urine exosome microRNA were extracted from a discovery cohort (n=22) whose baseline 
characteristics are shown in Table 1; they included healthy controls with normal kidney 
function (n=6), and ADPKD patients with early (eGFR >60ml/min/1.73m2, n=7) and late 
disease (eGFR <60ml/min/1.73m2, n=9). Although the mean age of the controls was lower 
than both patient groups, these differences were not statistically significant. There were 
expected differences in eGFR and serum uric acid between the groups. Mean kidney length 
and historical annualised eGFR decline (ml/min/yr over 5 years) were also significantly 
different between patients with early and late disease. Otherwise, all three groups were well 
matched. 
 
Principal Component Analysis (PCA) of the miRNA sequencing data demonstrated 
clustering of individual patient groups with the clearest separation between controls and 
ADPKD patients with late disease; patients with early disease overlapped with both 
controls and those with late disease (Figure 1A). Heat maps further displayed separation 
of the three groups with the lowest expression of multiple individual miRNAs evident in 
the ADPKD group with late disease (Figure 1B). 
 
A total of 23 miRNAs were identified by differential expression analysis to be significantly 
different between the three groups (Figure 1C). Of interest, all were significantly 
downregulated in ADPKD patients with late disease compared to the healthy controls. An 
intermediate pattern was observed in patients with early disease with a marked decrease in 
certain miRNA whereas others were less altered compared to controls (Figure 1C). In 
particular, expression of seven kidney-enriched miRNAs, ie the miR-194-2 cluster (miR-
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192-5p, miR-194-2-5p), miR-194-1-5p and four members of the miR-30 family (miR-30a-
5p, miR-30b-5p, miR-30d-5p, miR-30e-5p) were decreased (Figure 1C). Expression of all 
7 miRNAs was lower in ADPKD patients compared to controls, with a significant change 
in patients with late disease. In patients with early disease, only miR194-1-5p and miR194-
2-5p were significantly lower than controls (Figure 1D). Although these paralogs result in 
an identical mature miR-194 transcript, they are located on separate gene loci ie the miR-
192-miR-194-2 cluster (11q13.1) and the miR-215-miR194-1 cluster (1q41.1) 19. 
Interestingly, miR-192, miR-194 and miR-215 have been reported to be part of a human 
kidney-specific miRNA cluster 19 and miR-192 and miR-194 are also highly enriched in 
normal rat kidney with increased cortical expression relative to medulla 20.  
 
Although less highly expressed, members of the miR-30 family display a restricted 
expression pattern in the amphibian pronephric kidney and mouse metanephric kidney 
where they play an essential role in promoting Xenopus terminal nephron differentiation 
(in particular miR-30a-5p but also miR-30d-5p, miR-30e-5p) 21 and in the normal 
maintenance of mouse podocytes 22. Since the most abundant and tissue-specific miRNAs 
in the cell are likely to mediate target mRNA suppression 23, we chose to study five 
candidate miRNAs representing the miR-194-2 cluster and the miR-30 family.  
 
Validation of differentially expressed kidney enriched exosomal miRNAs by qPCR 
To validate these findings, patients were recruited from a tertiary specialist PKD clinic 
following-up over 500 patients 24. A validation cohort of 40 patients (n=20 with eGFR>60, 
n=20 with eGFR<60) was selected based on matching for age, gender, baseline eGFR and 
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availability of urine samples. The sample size of 40 patients was calculated based on a 
historical eGFR slope < or > 3 ml/min/yr (over 5 years), and provided 80% power to detect 
an odds ratio of 2.5 and type 1 error (alpha level) of 0.05 using a z test. The baseline clinical 
characteristics of this cohort, which includes 20 healthy controls, are shown in Table 2. 
Overall, all three groups were well matched with no difference in baseline eGFR between 
controls and ADPKD patients with early disease. As expected, patients with late disease 
also had significantly bigger kidneys as evidenced by increased mean kidney length (MKL), 
more rapid historical eGFR decline and increased proteinuria (Table 2). Total Kidney 
Volume (TKV) or height-adjusted TKV (ht-TKV) measured from renal MRI was only 
available in 50% of patients in this cohort performed for clinical or other indications. MKL 
was significantly correlated with both TKV and ht-TKV (Figure S1A). In this subgroup, 
there was an enrichment of patients with Mayo Imaging Class 1C-E in patients with late 
disease (7/11) compared to those with early disease (4/9) (Table 2) 25. There was however 
no difference in the frequency of PKD1 mutations between early and late groups (Table 
2). 
 
Unlike the discovery cohort, serum uric acid was not different between the control and 
patient groups. There was a higher frequency of hypertension and use of angiotensin 
receptor blockers (ARB) or Angiotensin Converting Enzyme inhibitor (ACEi) in the group 
with late disease. There were no differences in relevant co-morbidities between early and 
late patient groups: type 2 diabetes mellitus (2 early v 1 late) or gout (3 early v 2 late). 
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miRNA expression for all five miRNAs was validated by qPCR in total urine exosome 
miRNA using Taqman-specific primers: primers for miR-194-5p detected transcripts from 
both miR-194-1 and miR-194-2 paralogues. As shown in Figure 2A, expression of all five 
miRNAs was significantly reduced in ADPKD patients with late disease compared to 
healthy controls. In patients with early disease, only miR-192-5p showed a significant 
decrease when compared to healthy controls (fold change 0.54) (Figure 2A). To 
investigate whether these changes were specific to ADPKD or reflected changes common 
to Chronic Kidney Disease (CKD), we analysed urine exosome samples from a separate 
CKD patient cohort (n=24) with Type 2 diabetes mellitus (T2DM) alongside a group of 
healthy controls (n=10). Although the mean age of this cohort was higher than the ADPKD 
patients with late disease in the validation cohort (63.3 ± 10.7 v 54.0 ± 9.8 yrs), their eGFR 
was comparable (37.4 ± 13.4 v 34.8 ± 12.6 ml/min/1.73m2) (Table 2). In the CKD group, 
changes for these five miRNAs showed a different pattern to ADPKD but did not reach 
statistical significance (Figure 2B). However, there was a trend towards decreased miR-
30a, miR-30d and miR-30e expression with an opposite trend to increased miR-192 and 
miR-194 expression compared to healthy controls (eGFR>90 ml/min/1.73m2). 
 
Validation of differentially expressed kidney enriched miRNAs in a Pkd1 mouse 
model 
To validate that our findings in urine exosomes were an accurate reflection of the cystic 
kidney, we isolated miRNAs from Pkd1nl,nl mouse kidneys at different ages (2, 4 and 10 
weeks) after birth, representing early, middle and late disease 26. Differential expression of 
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all five miRNAs was then measured by qPCR in mutant kidneys and their normal 
littermates at the three time points. 
 
As in human ADPKD urine exosomes, expression of all five miRNAs was significantly 
decreased in Pkd1 mouse kidneys compared to wild-type littermates (Figure 2C). However, 
the temporal expression pattern for each miRNA was not identical. Changes in the miR-30 
miRNA were observed in early disease (2 weeks) but were no longer significant in late 
disease (10 weeks). In contrast, expression of miR-192-5p and miR-194-5p were 
significantly decreased at all time points measured. 
 
Profiling of differentially expressed kidney enriched miRNAs in human PKD1 cystic 
and control kidney tissue 
Next, we interrogated an independent miRNA microarray study that profiled the expression 
of 1,145 miRNAs in 16 renal cysts of different sizes and 6 minimally cystic tissue (MCT) 
derived from 4 polycystic kidneys or 4 normal renal cortical samples. By using the top 200 
or 500 most variable miRNAs across all samples in an unsupervised hierarchical cluster 
analysis27, 28 a matrix of Pearson correlation coefficients that indicate the degree of overall 
similarity between any two samples was derived (Figure S2A). We found that the MCT 
and normal renal cortical samples showed the most homogeneous pattern of global miRNA 
expression, while cyst samples exhibited greater heterogeneity, with 11 of 16 cyst samples 
clustered as a single group and others resembling the MCT group; the cyst clustering 
profile was independent of cyst size and patients. We also noted all technical replicates 
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clustered together, supporting the robustness and reproducibility of the miRNA gene 
expression profiles.  
 
Differentially expressed miRNAs in PKD1 renal cysts compared with MCT and 
normal renal cortical samples  
To identify the miRNAs that best discriminated the cysts from MCT and normal renal 
cortical samples, we used SAM multiclass analysis29. At FDR ≤ 0.1% to control for 
multiple testing, 158 miRNAs with medium to high expression levels were identified as 
significant (Table S1) and were then subjected to supervised hierarchical clustering. We 
found all cyst samples clustered as a single group, while the MCT and normal renal cortical 
samples once again clustered as a second group (Figure S2B). 
 
The examination of 158-miRNA gene clusters revealed 4 distinct miRNA expression 
patterns (Figure 3A): two major sets whose expressions were down or up-regulated solely 
in cysts vs. MCT and normal kidney samples, including 81 down and 53 up-regulated 
miRNAs, and two minor sets whose expressions were down or up-regulated in both cysts 
and MCT vs. normal kidney samples, including 18 down and 6 up-regulated miRNAs. It 
had been previously demonstrated that miRNAs in genomic clusters can be co-expressed 
30. Among the 158 dysregulated miRNAs, 76 were located in 23 genomic clusters with at 
least 2 miRNAs within a proximal 50kb distance on a chromosome (Table S2). In each of 
19 genomic clusters, all differentially expressed miRNAs displayed concordance in their 




miR-192 and miR-194 have been shown to be more highly enriched in the renal cortex than 
the medulla 20. In renal cysts, these miRNAs were among the miRNAs with the highest 
rank and fold changes based on SAM analysis (Table S1). According to the expression 
level of miRNAs in our 4 normal kidney tissue samples, the average signal intensity for 
miR-192-5p, miR-194-5p and miR-215-5p was 28000, 34000 and 4800, respectively, 
suggesting the mature forms of miR-192 and miR-194 are mainly from the mir-194-2-192 
cluster in normal kidney. We confirmed these findings by qPCR in patient samples 
representing minimally cystic tissue (MCT), small cysts (SC <1ml), medium cysts (MC 
10-30ml) and large cysts (LC >50ml). As shown in Figure 3C, significant decreases in all 
5 miRNA were found even in MCT (non-significant reduction for miR-30a-5p) compared 
to normal tissue indicating that these changes were detectable in human kidney tissue at 
the earliest stages of disease. 
 
miRNA expression correlates with markers of disease and can predict progression 
We decided to use MKL was a surrogate marker of kidney volume instead of MRI-TKV 
in this cohort as TKV measurements were only available in 50% of the validation cohort 
(Table 2). MKL has also been shown to be as reliable as htTKV as a prognostic marker for 
GFR decline in the CRISP cohort 31. In ROC analysis, we found that MKL was highly 
predictive of baseline eGFR (AUC 0.905) although less so in discriminating between slow 
and rapid progressors (AUC 0.634, see below) (Figure S1B).  
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All five microRNAs showed significant negative correlations with baseline eGFR and 
positive correlations with MKL indicating that microRNA expression decreased with 
disease progression (Figure S3). Linear regression analysis was performed to identify 
significant correlations between individual microRNAs and other clinical variables (Table 
S3). In univariate analysis, miR-30a-5p, miR-30e-5p and miR-192-5p each showed 
significant correlations with baseline eGFR, eGFR slope and MKL. Additionally, miR-
30e-5p and miR-192-5p were significantly correlated with PCR whereas miR-30d-5p was 
significantly correlated with serum uric acid. Correlations between miR-194-5p with 
baseline eGFR (p=0.055) and MKL (p=0.069) just failed to reach significance (Table S3). 
In multiple regression analysis, baseline eGFR remained significantly associated with the 
miR-30-family while MKL remained significantly associated with miR-192-5p. MiR-30d-
5p was also significantly associated with serum uric acid levels (Table 3). 
 
The ability of urine exosomal microRNAs to discriminate between ADPKD patients with 
slowly versus rapidly progressive disease (annual eGFR slope < or > 3 ml/min/year over 5 
years) in this cohort was next calculated using ROC curve analysis 32 (Figure S4). MiR-
30e-5p showed the highest AUC (0.826) whereas MKL had the lowest ROC value (0.634). 
In this cohort, a combination of all five microRNAs (AUC 0.889) proved superior to MKL 
but the combination of both miRNA and MKL further improved the ability to discriminate 
patients with a slowly progressive disease from those with rapidly progressive disease 
(AUC 0.914) (Table 4).  
 
Identification of predicted target genes of individual exosomal miRNAs 
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Next, we sought to identify the predicted target genes of miR-30 and miR192/miR194 
families using the miRWalk database since these could potentially identify new therapeutic 
targets or disease biomarkers. A total of 11 significantly enriched pathways were identified 
using the DAVID pathway program (Table S4). Of interest, the top 4 pathways common 
to both miR families were related to Wnt signaling, MAPK signaling, ErbB signaling and 
Calcium signaling. 
 
In silico predictions of novel miR-mRNA target genes 
Our previous global mRNA profiling on cysts of different size and minimally cystic tissue 
from PKD1 human polycystic kidneys identified 6764 (up: 4515; down: 2249) 
differentially regulated genes and 212 (128 up- and 84 down-regulated) pathways from a 
total of 20488 unique genes with gene symbols in renal cysts respectively18. To test which 
miRNA target genes were inversely correlated to the expression of the respective miRNAs 
in these samples, we compared the predicted miRNA target genes identified by TargetScan 
5.1 33 to the differentially regulated mRNAs 18 and obtained the number of predicted 
mRNAs that showed increased expression in PKD1 renal cysts. At the p < 4.67xE-04 level 
using a two-tailed Fisher's Exact Test with the Bonferroni Method for multiple testing 
correction, 56 down-regulated miRNAs from 42 families had a significant number of target 
mRNAs that were up-regulated (Figure 3B, Table S5). Using GSEA 34, we tested 6319 
target genes predicted for the 42 down-regulated miRNA families and observed enrichment 
for 50 gene pathways, 47 of which overlapped with the previously identified 128 up-
regulated pathways in renal cysts 18 including mitogenic signaling pathways via RTKs, cell 
cycle, Wnt, Notch, TGFβ and EMT (Table S6). Specific miRNA-target genes for the miR-
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192/miR-194-2 cluster and members of the mir-30 family (miR-30a-5p, miR-30b-5p, miR-
30c-5p, miR-30d-5p and miR-30e-5p) were then identified and integrated with the 
differentially up-regulated genes from our previous study (Figure 4).  
 
miR-192 and miR-194 regulate proliferation in ADPKD cyst assays. 
Both miR-192 and miR-194 showed significant decreases at all time points in mouse 
ADPKD tissue and the strongest down-regulation in human ADPKD tissue. We therefore 
tested the effect of miR-192 and 194 mimics in a 3D matrigel cyst assay. Human ADPKD 
cells (OX161 c1) were transfected with miR mimics or miR negative control mimics and 
cultured in matrigel for 12 days to form cysts. Expression of both miR-mimics led to a 
significant decrease in cyst area compared to scrambled miR controls (Figure 5A). This 
was associated with a significant reduction in proliferation (Ki67 positive cysts) (Figure 
5B) but not in apoptosis (cleaved-caspase 3 positive cysts) (Figure 5C). 
 
Identification of a miR-194-5p/PIK3R1 functional interaction 
One of the genes predicted to be regulated by both miR-30 and miR-194 was PIK3R1. 
PIK3R1 encodes p85, the major regulatory subunit of phosphoinositide 3-kinase (PI3K) 
which associates with the catalytic subunit encoded by PIK3CA. PI3K is a master regulator 
of cellular function, being activated by multiple inputs to in turn regulate proliferation, 
apoptosis, vesicular transport and polarity amongst many reported functions35. We found 
that the expression of PIK3R1 was highly upregulated by several fold (4-6x) in human and 
mouse cystic cells or kidneys compared to controls (Figure 6A). This was confirmed by 
immunoblotting for PI3K-p85 in human cystic cells (Figure 6B, S5). Of interest, 
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expression of PIK3CA and its protein (p110) were similarly increased in human cystic 
cells although with a lower fold change (Figure 6B, C). Examination of the 3’UTR of 
PIK3R1 revealed a conserved seed sequence for miR-194-5p, a finding not previously 
described in the DIANA-TarBase v8 database. Using a luciferase reporter assay, we 
demonstrate that binding of a miR-194-5p mimic to this sequence significantly reduced 
luciferase activity, confirming that PIK3R1 is a functional mRNA target of miR-194-5p 
(Figure 6D). Mutation of the seed sequence eliminated the interaction with miR-194-5p 
demonstrating the specificity of this interaction (Figure 6E).  
 
In a previous paper, we reported that human PKD1 cystic cells showed a hyperproliferative 
response to IGF-1 compared to non-cystic controls and that this was mediated by both PI3K 
and ERK signaling pathways36. In the microarray of human ADPKD cysts reported in this 
paper, the IGF-1 signaling pathway was also highly upregulated ranking 9th overall (Table 
S6). To investigate the functional effects of PIK3R1 in a relevant system, we tested the 
effect of IGF-1 on cyst formation in OX161c1, a human cystic line which expresses high 
levels of PIK3R1 and PI3K-p85 (Figure 6A, B). IGF-1 stimulated cyst growth in these 
cells, a response that was completely inhibited by either knockdown of PIK3R1 (Figure 
S5) or the chemical PI3K inhibitor LY29004 (Figure S6). These findings confirm that the 
upregulation of PIK3R1 is functionally relevant to cyst expansion in ADPKD. 
 
Identification of a miR-194-5p/ANO1 functional interaction 
To further validate the usefulness of this approach to identify new therapeutic targets, we 
investigated the possible interaction between mir-194-5p and the calcium-activated 
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chloride channel, anoctamin-1 (ANO1), a prediction also not described in the DIANA-
TarBase v8 database. ANO1 had been identified as a potential contributor to epithelial 
chloride (and hence fluid) secretion in in vitro cyst models although its functional role in 
vivo has not yet been proven37. In a recent microarray study, we found that ANO1 
expression was highly up-regulated in human PKD1 cystic epithelial cells38; increased 
expression of ANO1 was also observed in the PKD1 renal cyst microarray (with 3.7-fold 
vs MCT, data not shown). In silico analysis predicted that ANO1 mRNA was a predicted 
target for miR-194-5p although this had not been experimentally validated.  
 
We first confirmed that ANO1 expression was differentially increased in cellular and 
mouse models of ADPKD. Ano1 expression was increased by 3.7 and 2.5-fold respectively 
in 4 week and 10 week Pkd1 mice compared to their wild-type littermates (n=6 per group) 
(Figure 7A). In mouse embryonic kidney cells (MEK) derived from E15.5 collecting ducts 
of a different Pkd1 mutant39, a 2.9 fold increase in Ano1 was also observed in mutant 
compared to wild-type cells (n=3, data not shown). We next profiled ANO1 expression in 
four human PKD1 cystic lines (OX161C1, OX938, SKI001, SKI002) and compared them 
to 5 human control kidney lines (UCL93, RFH94, CL5, CL8, CL11) 36. Overall, the mean 
fold changes in PKD1 cystic cells were significantly different from control cells although 
there was a greater variation in ANO1 expression between the four lines compared to 
PIK3R1 (Figure 7B). 
 
The 3’UTR of ANO1 mRNA contains two predicted binding seed sequences for miR-194-
5p. By deletion analysis, we showed that the first of these (993-999bp) bound to miR-194-
 18 
5p in luciferase reporter assays, while the second (1258-1264bp) was neutral (Figure 7C). 
Mutation of the seed sequence eliminated the interaction with miR-194-5p demonstrating 
the specificity of this interaction (Figure 7C). Blocking ANO1 expression (by siRNA) or 
action (with the specific antagonist CaCCinh-A01) inhibited the growth of human PKD1 
cystic cells (SKI001) in 3D cyst assays (Figures 7D, S5). Our results extend previous in 
vitro data using dog (MDCK) and embryonic mouse kidneys to human disease cells37. 
Importantly, we identify and confirm for the first time a hitherto unknown miR-194-
5p/ANO1 interaction. Interestingly, ANO1 is located close to the miR-192-miR194-2 
cluster on 11q.13. Overall, these findings support a translational strategy to target ANO1 
in ADPKD.  
 
DISCUSSION 
In this study, we have taken an unbiased approach to identify differentially expressed 
miRNA from human ADPKD urine exosomes using global miRNA sequencing. Unlike 
experimental models, we were able to correlate our findings with commonly used clinical 
markers of disease such as baseline eGFR, eGFR slope and MKL as a relevant surrogate 
for total kidney volume (TKV) to test their potential as disease biomarkers.  
 
Surprisingly, we only identified 23 exosomal miRNAs that were significantly altered in 
ADPKD compared to healthy controls in a discovery cohort. Nevertheless, the 
identification of several members of the kidney-enriched miR-30 family and the miR-
192/miR-194 gene cluster led us to validate these miRNAs in a larger validation cohort. 
The changes determined in urine exosome miRNA were confirmed in kidney miRNA 
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isolated from an established mouse Pkd1 model showing that they were reflective of 
intrinsic changes in the diseased kidney. We also confirmed these changes in a unique 
sample set derived from human ADPKD cysts including tissue from minimally cystic 
tissue (MCT) and cysts of different sizes. These findings revealed that for these five 
differentially expressed miRNAs, a decrease was already detectable in MCT indicating 
these are likely to be primary or early changes in the disease process. Furthermore, by 
selecting potential mRNA targets recognized by these miRNA from previously identified 
upregulated genes in the same tissues18, we were able to identify several enriched pathways 
and potential target genes. Finally, as an example of potential identification of novel 
therapeutic targets, we provide the first evidence of a functional interaction between miR-
194-5p and two genes, PIK3R1 and ANO1.  
 
During the writing of this manuscript, another group reported that miR-192-5p and miR-
194-5p were significantly downregulated in human end-stage ADPKD kidney tissue by 
differential miR microarray 40. Of interest, these changes were negatively correlated to 
hypermethylation of the common promoter for miR-192/194-2 in ADPKD compared to 
non-ADPKD kidneys. In this study, a total of 65 miRs were differentially expressed by at 
least 1.5-fold. Of relevance to our results, miR-30b-5p and miR-30d-5p were also found to 
be downregulated although interestingly, without promoter hypermethylation. We 
conclude that apart from promoter hypermethylation, other factors may result in 
downregulation of mature miRNA expression in ADPKD. These could include the 
deregulation of transcriptional control (eg p53, HNF, TAZ/YAP) or secondary changes in 
the miRNA biogenesis pathway (eg Dicer)41-43. Of interest, several key transcription factors 
implicated in other ADPKD models (p53, HNF1A, HNF1B, HNF4A) have also been 
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shown to regulate the miR-192/miR-194-2 cluster (Figure 4) 44, 45. Otherwise there was 
limited overlap with the miRs that we identified in our study. Of interest, we also detected 
differential expression of two miR reported to be more enriched in renal medulla (miR-
27b, miR-99a) 20 although these were not detected in this study. These differences could 
relate to the stage of disease studied (end-stage kidneys) or be secondary to changes in 
renal function.  
 
To investigate whether these miRNAs were specifically altered in ADPKD or common to 
other forms of CKD, we analysed an independent cohort comprised of patients with CKD 
secondary to T2DM. Our results indicate that in contrast to ADPKD, miR-192-5p and 
miR-194-5p showed a trend of increased expression relative to controls. This suggests 
that the changes we have detected are likely to be specific to ADPKD for these two 
miRNA. Of interest, miR-192-5p expression was increased in the renal cortex and 
glomeruli of streptozotocin-induced diabetic mice where it was functionally linked to 
diabetic glomerular hypertrophy, mesangial expansion and proteinuria 46. Similar 
increases in miR-192-5p have been reported in studies of renal biopsy tissue from 
patients with IgA nephropathy and hypertensive nephrosclerosis 47, 48 probably relevant to 
glomerular-specific changes in miR-192-5p expression (see below). 
 
For miR-30a-5p, miR30b-5p and miR-30e-5p, we noted a similar non-significant trend to 
decreased expression compared to controls. This could indicate that changes for the 
miR30 family may be common to both ADPKD and T2DM although further 
confirmatory studies will be required. Nonetheless, they could point to clinically and 
biologically important pathways common to CKD regulated by miR-30 members. A 
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previous study in microdissected nephron segments obtained from male adult rat kidneys 
showed miR-192-5p and miR-194-5p were highly enriched in proximal tubule (PT) 
segments compared to the medullary thick ascending limb (mTAL) while miR-30a-5p 
and miR-30e-5p showed the reverse; all four miRNA were enriched in tubular segments 
compared to glomeruli 49. Our results suggest the likelihood of exosomes arising from 
multiple cysts of different segmental origin or non-cystic tubules (and glomeruli) that 
might be secondarily involved in the disease process (eg due to compression, ischaemia 
or inflammation) in a non-cell autonomous manner. The use of urine exosomes could 
therefore provide a global picture of the many processes determining disease progression 
in vivo, both cystic and non-cystic, in ADPKD kidneys 50. A previous study linked miR-
192-5p in regulating the expression and function of the 1 subunit of Na+/K+-ATPase in 
rat PT 49 and WNK1 expression in mouse distal tubule (DT) segments 51. Given their 
importance in regulating tubular sodium reabsorption, the reduction in miR-192-5p 
observed may also be relevant to the pathophysiology of hypertension observed early in 
ADPKD 52. 
 
One striking difference between our results and those reported from rodent models was the 
lack of common differentially expressed miRNAs. We did not identify upregulated miRNA 
such as those reported in murine Pkd1 models (miR17-92 cluster) or miR-2112, 13.  Possible 
explanations are differences in species, pathogenic mutations, disease pathogenesis, 
disease stage, tissue type or methodology used.  For instance, a study in a mouse model of 
PKD (Kif3a-KO) found up-regulation of miR-17~92 in 21d-old and 28d-old (cyst growth) 
but not in 10d-old and 14d-old mice (cyst initiation)12. The discrepancy in the expression 
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of miR-17~92 cluster between our results and this study may due to differences in species 
(human vs mouse), mutation types (PKD1 vs Kif3A) as well as disease stages (late vs 
middle). 
 
In summary, we have identified a novel subset of urinary exosomal miRNAs that could 
serve as potential biomarkers of disease progression and suggest new therapeutic targets in 
ADPKD. These results are clearly relevant to human disease but were also confirmed in a 
mouse model of ADPKD. By taking a global approach using urinary exosomes and human 
cystic tissue, we have also identified several other miRNA families for future study. 
Integrating these findings within a wider gene regulatory network (eg derived from the 
microarray dataset of upregulated genes) will be the next step since typically, multiple 
miRNAs may regulate one mRNA, and one miRNA may target several hundred different 
genes, thus reflecting cooperative translational control and target multiplicity 53. The 
changes we have described make an important contribution to understanding disease 
pathogenesis, defining new disease biomarkers and identifying new drug targets to slow 
disease progression in ADPKD.  
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MATERALS and METHODS 
Study Participants and Ethical Approval 
Ethical approval for this study was obtained from the National Research Ethics Service 
Committee Yorkshire and The Humber Bradford (REC12/YH/0297) and from the REB of 
the Toronto General Hospital (02-0036). 
 
Isolation of urinary extracellular vesicles and extraction of miRNAs 
Urinary extracellular vesicles (UEVs) or exosomes were isolated by differential 
centrifugation as previously reported38. In brief, 10 ml of urine were initially centrifuged 
at 17,000 g for 15 min. The supernatant was retained and the pellet was resuspended in 200 
µl isolation buffer (250 mM sucrose, 10 mM triethanolamine pH 7.6, 50 µl of DTT) to 
reduce the highly abundant Tamm-Horsfall protein. Following incubation at room 
temperature for 5 min, the sample was briefly vortexed and centrifuged again at 17,000 g 
for 15 min. This supernatant was then combined with the initial supernatant and centrifuged 
once more at 170,000 g for 150 min. Urinary exosomal associated microRNAs were 
isolated from the exosome pellet using a miRCURY™ RNA cell and plant isolation kit 
(Exiqon) according to the manufacturers protocol. Due to the discontinuation of this kit, 
we used the miRNeasy Micro kit (Qiagen) for the later study on patients with CKD. 
 
Differential expression of miRNAs 
The raw reads obtained were processed using bcl2fastq conversion software (Illumina). 
The data was de-multiplexed according to their specific barcode codes into FASTQ format. 
Before proceeding to identify differentially expressing microRNAs, an overview of the 
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data quality was performed. The quality of generated data was checked using the default 
settings of Strand NGS. The quality check of FASTQ data is based on a PHRED quality 
score 54-56 and all the sequencing reads from this study had a quality score > 30, denoting 
that the base call accuracy of overall reads is 99.9%. The size distributions of sequencing 
reads were evaluated for all samples showing reads were compatible with the size range 
for miRNA (19-24nt). A total of 74.22% of the mean sequencing reads were mapped to the 
human genome (hg39). To detect and profile miRNAs in our small RNA high-throughput 
sequencing data we used Strand NGS software by creating a small RNA analysis 
experiment. Default parameters were used for alignment quality controls and for further 
data analysis steps. The expression level of the raw counts was normalised between 
samples using the default DeSeq normalisation algorithm. Normalised counts were then 
log transformed to yield normalised signal values used for all the statistical tests and plots. 
False discovery rate (FDR) cutoff value for differentially expressed miRNAs between 
control and treated samples was set at FDR = 0.05 and the expression threshold was 





A ROC curve calculation relies on the fraction of true positives (study sensitivity) and false 
positives (1 - sensitivity). The area under the curve (AUC), confidence interval (CI), p 
values of all calculated ROC curves and the ROC curves for each individual microRNA 
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are displayed together with cut-off values of the differentially expressed microRNAs 
together with their corresponding sensitivity and specificity (Table 4, Figure S3). 
 
Statistical analysis  
Data are presented as means values ± SE. Student's t-test or ANOVA was used for 
statistical analysis with a P < 0.05 indicating statistical significance. The degree of 
significance as determined by GraphPad Prism software is denoted as follows: *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
 
See the Online Supplement for description of other methods used in this study. 
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Figure 1. miRNAseq identifies differential expression of miRNAs from ADPKD 
urinary exosomes 
(A) Principal component analysis of the miRNAseq data from healthy control, early 
(GFR>60) and late (GFR<60) ADPKD patients generated using ClustVis software. (B) 
Heat map showing expression of differentially expressed miRNAs in individual healthy 
control, early (GFR>60) and late (GFR<60) ADPKD patients generated using ClustVis 
software. (C) Expression of differentially expressed miRNAs in individual healthy control, 
early (GFR>60) and late (GFR<60) ADPKD patients. (D) Expression of individual kidney 
enriched miRNAs by DeSeq normalised signal values between healthy control, early 
(GFR>60) and late (GFR<60) ADPKD patients. 
 
Figure 2 Quantitative PCR (qPCR) validation of differentially expressed kidney 
enriched miRNAs in human urine exosomes and Pkd1 mouse kidney 
(A) qPCR showed significantly lower expression of all 5miRNAs in late ADPKD 
(GFR<60) compared to healthy controls. (B) qPCR showed no significant difference in all 
5 miRNA expression between healthy controls and a non ADPKD CKD cohort. (C) 
Differential expression of miR-30a-5p, miR-30d-5p, miR-30e-5p, miR-192-5p and miR-
194-5p in Pkd1 mice (Pkd1nl,nl) at 2, 4 and 10 week old. Values are expressed as fold change 
over Pkd1wt,wt at the same age. Values are expressed as means ±SEM, n=5-6 animals per 
group. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 compared to Pkd1wt,wt at the same 
age. Statistical significance was determined using an unpaired t-test. 
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Figure 3 Quantitative PCR (qPCR) validation of differentially expressed kidney 
enriched miRNAs in human tissue samples 
(A) At FDR of 0.1%, SAM identified 158 miRNAs with differential expression among the 
3 groups: cysts, MCT and normal renal cortical samples. The 158-miRNA gene clustering 
depicts 4 groups of miRNAs. Abbreviations: SC (small cysts); MC (medium cysts); LC 
(large cysts); MCT (minimally cystic tissue); KIDNEY (normal renal cortical tissue), and 
re (technical replicate). (B) Pathways/genes predicted to be affected by 42 down-regulated 
miRNA families in PKD1 renal cysts (NOM p ≤ 0.05 and FDR ≤ 0.25 by GSEA). (C) 
Differential expression of miR-30a-5p, miR-30d-5p, miR-30e-5p, miR-192-5p and miR-
194-5p in human tissue samples was determined by Taqman qPCR. Values are expressed 
as fold change over normal renal cortex tissue. Statistical significance was determined 
using an unpaired t-test. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 
 
Figure 4 Schematic summary of the aberrantly activation of pathways (Growth 
factors/RTKs, Notch, Wnt/β-catenin, and TGFβ signaling pathways) in PKD1 renal 
cysts predicted to be affected by the selected down-regulation of miRNAs (miR-
192/194 and miR-30 family members, green letters in colored boxes).  
All experimentally supported miRNA-target gene pairs were obtained from DIANA-
TarBase v8 (http://www.microrna.gr/tarbase). Genes whose expression was up or down 
regulated are also shown in red or green letters with fold changes respectively (cyst vs. 
minimal cystic tissue; the number in bracket denotes fold-change). Genes that were not 
differentially expressed are shown in black. * denotes miRNA negatively regulates a given 
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target gene expression at the translational level. The mechanisms known to contribute to 
the downregulation of miR-192/194 are summarized in rectangle box. 
 
Figure 5 Inhibition of cyst growth in 3D matrigel cultures by miR-192 and 194 mimics. 
(A) Representative images of day 12 cysts following transfection with 50nM miR-192/194 
or negative control mimics. Mean cyst area was significantly reduced following 
transfection with miR mimics. (B) The number of cysts stained with the proliferation 
marker Ki67 was significantly reduced in cyst transfected with miR mimics indicating a 
reduction in the rate of proliferation. (C) No significant difference in the number of cleaved 
caspase-3 stained cysts was observed between miR mimics and negative controls. 
 
Figure 6 The miR-194-5p target gene PIK3R1 is increased in ADPKD models and 
mediated IGF-1-mediated cyst growth 
(A) Significant over-expression of PIK3R1 or Pik3r1 in ADPKD models detected by qPCR. 
Left panel: normal (WT, N=2) v PKD1 cystic human cells (N=4) - fold-change of 3.9 (n=3); 
Middle panel: Pkd1wt,wt (N=10) v Pkd1nl,nl (N=10) mice at 4 and 10 weeks - fold change 
of 3.3 and 2.26 respectively (n=3); Right panel: MEK wild-type (+/+) v MEK mutant (-/-) 
cells - fold change of 5.8 (n=3). (B) Over-expression of p85-α and p110-α in human PKD1 
cystic cells (n=4) compared to non-cystic cells (n=5) by Western blotting with a p85α/actin 
ratio value of 5.7-fold compared to WT and a p110α/actin ratio of 2.4 fold. (C) Increased 
expression of PIK3CA by qPCR in four human PKD1 cystic cell lines compared to two 
normal cell lines (n=3, 2.3-fold increase). (D) A predicted miR-194-5p site was identified 
in PIK3R1 between bp 2094-2100 in the 3’UTR (seed sequences shown in red) and cloned 
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into the pmirGLO luciferase reporter plasmid. Significant suppression of luciferase activity 
was observed in cells transfected with PIK3R1 3’UTR and a miR-194-5p mimic. The non-
targeting miRNA mimic used as a negative control had no effect on luciferase activity. (E). 
Mutation of two bp in the miR-194-5p seed sequence in the 3’UTR of PIK3R1 eliminated 
the suppression of luciferase activity demonstrating a specific interaction between miR-
194-5p and the 3’UTR of PIK3R1.  Mann Whitney test and SEM, **** p < 0.0001. 
Unpaired t-test and SEM, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
 
Figure 7 The miR-194-5p target gene ANO1 is overexpressed in ADPKD models and 
its inhibition reduces cyst growth 
(A) Ano1 expression by qPCR was significantly increased in 4 week (3.7-fold) and 10 week 
(2.5-fold) Pkd1 mice (Pkd1nl/nl) compared to control littermates (n= 6 per group). *p<0.05; 
**p<0.01; (B) Expression of ANO1 was significantly increased in human PKD1 cystic cell 
lines (n=4) compared to control non-cystic lines (n=5) with wide variation shown by fold 
changes of 1,059 (OX161c1), 20 (SKI001) and 200 (OX938). *p<0.05; (C) Two predicted 
miR-194-5p sites were identified in ANO1 by TargetScan between bp 993-999 and 1258-
1264 in the 3’UTR of ANO1 (seed sequences shown in red) and cloned into the pmirGLO 
luciferase reporter plasmid. Significant suppression of luciferase activity was only seen in 
cells transfected with ANO1 3’UTR between bp 993-999 and a miR-194-5p mimic. The 
non-targeting miRNA mimic used as a negative control had no effect on luciferase activity. 
Mutation of two bp in the miR-194-5p seed sequence in the 3’UTR of ANO1 eliminated 
the suppression of luciferase activity demonstrating a specific interaction between miR-
194-5p and the 3’UTR of ANO1 between bp 993-999.  (D) 3D matrigel cyst assays carried 
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out in the PKD1 line, SKI-001, in the presence of forskolin (10M). Cells were treated 
with the ANO1 selective antagonist CaCCinh-A01 (10 μM, A01), DMSO (control), a 
control scrambled siRNA (50 nM, Neg) or anti-ANO1 siRNA (50 nM, siRNA). Cyst areas 
were measured after 7, 12 and 19 days (n=80-179 cysts per time-point). ****/$$$$ Mann-
Whitney test and SEM. p < 0.0001. Representative images of cysts incubated with DMSO 
(control), CaCCinh-A01 (A01), negative control siRNA (Neg) or anti-ANO1 siRNA 
(siRNA) at 7, 12 and 19 d respectively. Scale bar: 25 μM 
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nd = not determined 
 
MKL = mean kidney length (ultrasound) 
 
PCR = Protein Creatinine Ratio 
  
Characteristic  Healthy controls 
(Mean ± SEM) 
ADPKD patients 
with eGFR > 60 
(Mean ± SEM) 
ADPKD patients 
with eGFR < 60 
(Mean ± SEM) 
P value 
Number 6 7 9 - 
Gender (F:M) 3:3 4:3 4:5 0.881 
Age (years) 46.00 ± 11.64 54.43 ± 10.98 53.67 ± 9.179 0.2987 
BMI (kg/m
2
) 28.22 ± 3.513 27.00 ± 2.708 25.33 ± 2.646 0.1872 
eGFR (ml/min/1.73 m
2
) 96.95 ± 24.55 99.71 ± 34.14 34.33 ± 17.56 < 0.0001 
MKL (cm) nd 13.28 ± 2.126 18.42 ± 2.041 0.0004 
eGFR slope (ml/min/1.73 m
2
) nd -0.3333 ± 3.470 -4.829 ± 2.105 0.0151 
Calcium (mmol/l) 2.348 ± 0.04119 2.333 ± 0.05376 2.283 ± 0.07297 0.1106 
Phosphate (mmol/l) 1.083 ± 0.1938 1.127 ± 0.1262 1.237 ± 0.1982 0.2437 
Uric acid (µmol/l) 375.0 ± 90.40 259.0 ± 29.69 414.0 ± 133.4 0.0186 
Cholesterol (mmol/l) 5.567± 0.9688 4.686 ± 0.8821 4.533 ± 0.9836 0.1259 
PCR (mg/mmol) nd 11.00 ± 1.732 24.88 ± 18.4 0.2399 
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controls (Mean ± 
SEM) 
ADPKD patients 
with eGFR > 60 
(Mean ± SEM) 
ADPKD patients 
with eGFR < 60 
(Mean ± SEM) P value 
Number  20 20 20 - 
Gender (M:F) 10:10 10:10 12:8 0.765 
Age (years) 46.15 ± 12.62 47.80 ± 11.79 54.00 ± 9.830 0.0829 
BMI (kg/m
2
) 25.94 ± 3.475 30.12 ± 4.554 26.56 ± 3.974 0.0064 
eGFR (ml/min per 1.73 m
2
) 92.16 ± 23.25 95.45 ± 24.47 34.80 ± 12.64 < 0.0001 
MKL (cm) nd 13.82 ± 2.243 18.61 ± 3.440 < 0.0001 
eGFR slope (ml/min/year) nd -0.2429 ± 3.283 -3.688 ± 2.085 0.0017 
Calcium (mmol/l) 2.320 ± 0.07152 2.333 ± 0.06789 2.291 ± 0.08811 0.2232 
Phosphate (mmol/l) 1.097 ± 0.1547 1.097 ± 0.1547 1.157 ± 0.1945 0.4468 
Uric acid (µmol/l) 311.0 ± 74.15 327.3 ± 90.32  390.5 ± 136.5 0.0559 
Cholesterol (mmol/l) 5.330 ± 0.9836 5.211 ± 1.149 4.675 ± 0.8735 0.1001 
PCR (mg/mmol) nd 11.08 ± 6.487 25.47 ± 21.82 0.0361 
PKD1/PKD2/NMD nd 13/3/4 14/2/4  
Mayo htTKV Class 
(1AB/1CDE/2) 
nd 6/4/1 (n=11) 2/7/0 (n=9)  
Hypertension (Y/N) 0/20 15/5 19/1  
ARB/ACEi (Y/N) 0/20 10/10 15/5  
 
nd = not determined 
 
PCR = Protein Creatinine Ratio 
 
MKL = mean kidney length (ultrasound) 
 
NMD = no mutation detected 
 
HtTKV = height adjusted Total Kidney Volume (Magnetic Resonance Imaging) 
 
ARB = Angiotensin Receptor Blocker, ACEi = Angiotensin Converting Enzyme Inhibitor  
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Table 3 Multivariate analysis of selected differentially expressed microRNAs 
Multivariate regression model adjusted to the variables which have significant 




PTH = Parathyroid hormone 





β (P value) 
miR-30d-5p 
Standardized 
β (P value) 
miR-30e-5p 
Standardized 
β (P value) 
miR-192-5p 
Standardized 
β (P value) 
miR-194-5p 
Standardized 











-0.214 (0.16) -0.236 (0.12) 
 
MKL (cm)  0.075 (0.655) 
 
0.134 (0.442) 0.533 (0.000) 
 
Uric acid (µmol/l) 
 
0.394 (0.010) 
   
PTH (mmol/l) -0.035 
(0.842) 
    
PCR (mg/mmol) 
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Table 4 ROC analysis for the differentially expressed microRNAs for dichotomised 
eGFR slopes. A perfect diagnostic test has AUC of 1 while a value of 0.5 indicates weak 
prediction ability. 95% CI indicates 95 confidence limits of the true AUC of the 
population. The cut-off value for each differentially expressed microRNAs, beside mean 
kidney length, were calculated based on the value that provided maximum sensitivity and 
specificity for ADPKD progression. Receiver Operating Curve (ROC), Area Under the 
Curve (AUC), CI; Confidence Intervals (CI), Mean Kidney Length (MKL). 
 
Variables  AUC 95% CI P value 
Cut-off value 
(delta CT) 
Sensitivity  Specificity  
miR-30a-5p 0.770 0.620-0.920 0.004 -2.49 77.3% 70.6% 
miR-30d-5p 0.765 0.620-0.911 0.004 0.088 72.7% 64.7% 
miR-30e-5p 0.826 0.695-0.956 0.000 -1.89 72.7% 82.4% 
miR-192-5p 0.785 0.644-0.926 0.002 1.03 81.8% 70.6% 
miR-194-5p 0.677 0.510-0.844 0.057 1.42 72.7% 41.2% 
MKL 0.634 0.453-0.815 0.157 14.55 cm 72.7% 41.2% 
Combination of 
microRNAs 











Supplementary Figures and Tables 
Supplementary Figure S1: (A) Linear correlations between MKL and TKV or ht-TKV 
in validation cohort where both measurements were available (n=19). (B) ROC analysis 
for MKL in predicting baseline eGFR (AUC 0.905) or discriminating eGFR slope (AUC 
0.634).  
Supplementary Figure S2: miRNA expression profiles of normal kidneys, MCTs and 
renal cysts based on the standardized signal intensities of (A) the top 500 most variable 
miRNAs and (B) 158 dysregulated miRNAs, derive a matrix of Pearson correlation 
coefficients that indicate the degree of overall similarity between any two samples.  
Supplementary Figure S3: miRNA expression correlates with eGFR and mean kidney 
length.  
Supplementary Figure S4: ROC analysis of differentially expressed individual 
microRNAs to predict rapid disease progression in ADPKD. 
Supplementary Figure S5: (A) Knockdown of PIK3R1 or ANO1 in the human cystic 
lines, OX161c1 or SKI-001 respectively, measured by qPCR; (B) Uncropped blots of 
PI3K-p85 and PI3K-p110 following IGF-1 stimulation (see Figure 5B) 
Supplementary Figure S6: Knockdown of PIK3R1 or chemical inhibition of PI3K 




Supplementary Table 1: Differentially expressed miRNAs in human PKD1 renal cysts 
identified by SAM (FDR ≤ 0.1%) 
Supplementary Table 2: Dysregulated miRNA clusters within a proximal 50kb distance 
on a chromosome in PKD1 renal cysts. 
Supplementary Table 3: Linear regression analysis for selected clinical and biochemical 
variables identifying independent associations with differentially expressed microRNAs. 
Supplementary Table 4: Pathway analysis using DAVID based on changes in the five 
differentially expressed miRNA. 
Supplementary Table 5: Selected down-regulated miRNAs in human PKD1 renal cysts 
identified by SAM (FDR <0.1%), whose expression were also inversely correlated with 
the expression of their target genes (p < 4.67E-04). 
Supplementary Table 6: Pathways predicted to be affected by 42 downregulated 
miRNA families as identified by GSEA at NOM p ≤ 0.05 and FDR ≤ 0.25. 
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miR-194-5p    AGGUGUACCUCAACGACAAUGU
 1 
Supplementary information (Magayr et al, KI) 
Supplementary methods 
Study Participants and Ethical Approval 
Ethical approval for this study was obtained from the National Research Ethics Service 
Committee Yorkshire and The Humber Bradford (REC12/YH/0297) and from the REB of 
the Toronto General Hospital (02-0036). Ethical approval for the urine exosome samples 
from the CKD patient cohort with Type 2 diabetes was obtained from the National 
Research Ethics Service Committees – West London & GTAC (REC 04/Q0406/25), and 
London Bloomsbury (REC 17/LO.2083). All participants gave their signed informed 
consent at the time of recruitment or donation of their nephrectomized kidneys for the 
human microarray study. ADPKD patients were recruited through the Sheffield Kidney 
Institute and healthy normal volunteers were recruited from laboratory staff. Following 
collection, urine samples were centrifuged at 1,000 g for 10 min at 4°C. Cell pellets were 
discarded and cell free supernatants stored at −80°C until further analysis. 
 
Library preparation and small RNA sequencing (miRNA-Seq) 
The Illumina® TruSeq Small RNA Sample Preparation Protocol was used to generate the 
small RNA libraries. This protocol works well for studying miRNA because it takes 
advantage of the structure of most small RNA molecules by ligating specific adapters to 
the 5`-phosphate and 3`-hydroxyl group, which are molecular signatures of their biogenesis 
pathway. The 3`and 5`adapters were ligated to the RNA and used as templates for reverse 
transcription to cDNA. To amplify the obtained cDNA, ligated samples underwent 13 
cycles of PCR. For the size selection of amplified cDNA libraries, PCR products were then 
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run on a 6% TBE gel with a custom ladder. The small RNA of approximately 140–160 bp 
in size was excised from the gel and incubated overnight. The incubated gel was eluted 
using a spin column. The obtained sequence libraries were then validated using an Agilent 
Bioanalyzer. Sequencing analysis was carried out using an Illumina HiSeq 2000 
sequencing platform with 50 nt single reads (Illumina, USA). 
 
Renal Cyst and Control Tissues  
Renal cysts of different sizes were obtained from 4 polycystic kidneys removed for medical 
reasons. The surgical technique was described in detail in our previous articleS1. Small 
cysts (SC) were defined as less than 1 mL, SC* between 1-5 mL, medium cysts (MC) 
between 10-25 mL, and large cysts (LC) greater than 50 mL. Minimally cystic tissue 
(MCT), which might have contained a few microscopic cysts from the renal cortex, was 
obtained as PKD control tissue from the same kidneys. Additionally, non-cancerous renal 
cortical tissue from four nephrectomized kidneys with isolated renal cell carcinoma was 
used as normal control tissue. For the microarray study, 16 cysts (SC, n=5; SC*, n=5 
(including 1 duplicate); MC, n=4 (including 1 duplicate), and LC, n=4), 7 MCT (including 
1 duplicate) and 4 normal renal cortical tissue samples were used. All the study patients 
were shown to have PKD1 by DNA linkage or documentation of a pathogenic mutation 
identified through DNA sequencing by Athena Diagnostics™. Informed consent was 
obtained from all patients and the Institutional Review Board of the hospital where the 
nephrectomy was performed approved the research protocol used for this study. 
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Microarray Analysis of Cyst and Control Tissues 
200 ng of total RNA were labelled and hybridized onto Illumina Human miRNA BeadChip 
V2 (12-array BEADChip format) according to the manufacturer's protocol at the 
Microarray and Gene Expression Facility of the Centre for Applied Genomics in the 
Hospital for Sick Children, Toronto. This array comprises 1145 assays, detecting more than 
97% of the miRNAs described in the Sanger miRBase v12 (http://www.mirbase.org/) S2. 
The miRNA names used in this manuscript were based on miRBase v12; the revised 
miRNA names based on miRBase v22.1 have been provided in the GEO submission 
(GSE133530). We repeated some samples in duplicate for a total of 36 expression profiles. 
We also arranged each of these replicated in separate arrays to reduce potential batch effect. 
Before data processing, we checked that all hybridization passed internal QC metrics 
(including array hybridization controls, negative controls, polyadenylation controls, oligo 
annealing controls, mismatch controls, extension controls, and contamination detection 
controls) and kept the 29 arrays met the Illumina acceptance criteria.  
 
QPCR validation of differentially expressed miRNA 
miRNA expression in isolated exosomes purified from human urine samples and human 
tissue samples was determined by Taqman qPCR according to the manufacturer’s protocol 
(Life Technologies). Following RNA extraction, cDNA was synthesized from ADPKD, 
normal cells, tissue samples and exosomes using specific miRNA RT primers. QPCR was 
carried out on an ABI7900 qPCR machine. NormFinder was used to identify suitable 
universally expressed microRNAs in or RNAseq experiment which assesses the stability 
of differentially expressed microRNA based on their expression variability and stability 
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values. Based on this, miR-191-5p was the most universally expressed microRNAs among 
the samples with a stability value of 94.714. Normalisation of expression was therefore 
carried out relative to urinary expression of miR-191-5p (an endogenous control) and cel-
miR-39-3p (an exogenous spike in control). 
 
Analysis of miRNA expression in mouse kidney 
To purify total RNA, kidneys were mechanically homogenized in 1 ml of Qiazol® Lysis 
Reagent (Qiagen) using pre-filled Triple-pure zirconium beads (Benchmark Scientific) in 
a benchtop microtube homogenizer (Benchmark Scientific) at 4 °C. Purification of total 
RNA were processed using the miRNeasy kit (Qiagen) according to the manufacturer’s 
instructions. Residual DNA fragments were digested after elution of total RNA performing 
a DNase treatment (Invitrogen). Total RNA was quantified on a NanoDrop™ 2000/2000c 
Spectrophotometer (Thermo Fisher Scientific) and 250 ng RNA were retrotranscribed 
using TaqMan™ MicroRNA Reverse Transcription Kit (Applied Biosystem) and 
amplified using TaqMan qPCR master mix No Amp UNG (Applied Biosystem) and the 
following specific primers to each miRNA: miR-30a-5P (000417), miR-30d-5p (000420, 
miR-30e-5p (002223), miR-192-5p (000491) and miR-194-5p (000493). Results were 
expressed as fold change over Pkd1wt,wt at the same age following the 2- Δ ΔCT Livak Method 




Total cell lysates were prepared and processed for Western blotting as described S3. Cells 
were solubilized in detergent lysis buffer (50 mM Tris, 0.14 M NaCl, 1% Triton X-100, 
and 0.5% NP40) supplemented with Complete protease inhibitors and PhosStop 
phosphatase inhibitors (Roche Diagnostics, Mannheim, Germany). ECL detection and 
quantification using a Biorad Chemidoc XRS+ system running Image Lab automated 
image capture and analysis software. All quantification was carried out on non-saturated 
bands as determined by the software from 3 independent experiments. 
 
Matrigel 3D cyst assays 
3D matrigel cyst assays were performed as previously described S4. In brief, OX161/C1 
cells (1x105/well) were mixed with 70 µl Matrigel (Becton Dickinson, UK), plated into 96 
well plates in triplicate and incubated for 30 min at 37°C to facilitate gel formation. Media 
was replaced every 2 d. The average cyst area was calculated by measuring cyst areas in 




Immunofluorescence staining of cysts was performed as previously described S4 . 
Antibodies to Ki67 and cleaved-caspase 3 (Cell Signalling, USA) were used at 1/100 
dilution. Alexa Fluor 488 or 594 secondary antibodies (Invitrogen, USA) were used at 
1/1000 dilution. Slides were viewed using an Imaging Systems inverted IX71 microscope 
(Olympus, Tokyo, Japan) configured for multifluorescence image capture. Images were 
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acquired using SimplePCI imaging software (Compix, Hamamatsu, PA). At least 300 cysts 
from 19 random fields were quantified and expressed as a percentage positive cysts per 
field. 
 
Luciferase reporter assays 
Two predicted miR-194-5p sites in ANO1 were identified by TargetScan between bp 993-
999 and 1258-1264 in the 3’UTR of ANO1. A predicted miR-194-5p site in PIK3R1 was 
identified by TargetScan between bp 2094-2100 (seed sequences shown in red). The ANO1 
3’UTR containing each sequence and the PIK3R1 3’UTR was cloned into a pmirGLO 
luciferase reporter vector and transfected into HEK cells with either scrambled control 
miRNA or miR-194-5p mimics (50nM). Changes in luciferase activity were measured as 
previously described S4. Site directed mutagenesis of seed sequences was carried out as 
described previously S4 . 
 
In silico prediction of miRNA-target pairs 
The miRNA-target pairs for seven mature miRNAs (i.e. miR-192-5p, miR-194-5p, miR-
30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p and miR-30e-5p) were obtained using an 
online database – DIANA-TarBase v8 (http://www.microrna.gr/tarbase), which constitutes 
an extensive repository, integrating ∼670,000 unique experimentally supported miRNA–
gene interactions from low-/high-throughput experiments S5.  
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Microarray Data Analysis 
Data Preprocessing and Normalization 
Scanned raw data images were processed with BeadStudio 3.4 (Illumina), a software 
package that performs visualization and normalization. We used the “Quantile” 
normalization method, as previously suggested for Illumina miRNA microarray 
experiments. The normalized intensities and detection p-values were exported and further 
adjusted for batch effect with the R package ComBat, using the non-parametric empirical 
Bayes method S6; ComBat successfully eliminated batch effects as evidenced by 
hierarchical clustering and improved Pearson correlation coefficient for the technical 
replicates. After normalization, the samples with replicates were averaged prior to 
subsequent analysis. As some miRNAs were either not expressed or non-detectable, we 
filtered out probes with median detection p value > 0.0001. This procedure reduced the 
number of miRNA probes from 1146 to 829 with detectable levels. Additionally, previous 
work suggests that only the most abundant microRNAs in a cell mediate target suppression 
S7, we gave higher priority to higher expressed miRNAs. According to the average 
expression level of miRNAs in any of 3 renal groups, we assigned each miRNA into highly 
expressed (H): signal intensity between 10000 to 40000 (156 out of 829), moderately 
expressed (M): between 1000 to 10000 (328 out of 829), and low expressed (L): <1000 
(345 out of 829). Microarray data is MIAME compliant and available in Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) (ID: GSE133530).  
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Hierarchical Cluster Analysis (HCA) 
The detail procedure for HCA has been described in our previous article S1. In brief, we 
performed HCA based on miRNA expression from the top 200, or 500 most variable 
miRNAs (with the largest CV) across all samples to define the similarity of miRNA 
expression patterns between renal cysts of varying size, MCT and normal renal cortical 
tissue. HCA was performed to assess the relatedness of each case to every other case using 
dCHIP S8. The correlation coefficient matrix containing all pairwise correlation coefficients 
was created by dChip for heat-map visualization. The range of observed correlation 
coefficients was -0.8 to 0.8. Positive correlation is indicated by red and negative correlation 
by green. The degree of correlation is represented by color intensity. 
 
Statistical Analysis of Individual Differentially Expressed miRNAs 
Significance Analysis of Microarrays (SAM) was used to provide conventional measures 
of statistical significance for the individual miRNAs that are differentially expressed 
between classes S9. The SAM software works as a Microsoft Excel add-in and is available 
via http://www-stat.stanford.edu/~tibs/SAM/. We used a false discovery rate (FDR) ≤ 0.1% 
for these individual miRNA comparisons. To reduce the noise, we only focused on 
miRNAs with medium to high average expression. 
 
Bioinformatic Analysis 
In silico sequence analysis predict the presence of hundreds of thousands of miRNA-target 
pairs, only a small number of which have been experimentally validated, which usually 
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have the evidence of reciprocal expression between the miRNAs and the targets. We used 
TargetScan 5.1 (http://www.targetscan.org/) S10 for prediction of potential miRNA target 
genes, as it was shown to be superior to other target predictors S11. By TargetScan, miRNAs 
that belong to the same family (a set of miRNAs sharing the same seed sequence, nt 2-8) 
were grouped together and then each family was then further assigned into 3 TargetScan 
families: broadly conserved, conserved or poorly conserved family, according to the 
evolutionary conservation among species. For each predicted target gene of highly 
conserved miRNA families, TargetScan calculated an Aggregate PCT (the probability of 
conserved targeting) score, which reflects the probability of preferential conservation and 
has the advantage of identifying targeting interactions that are not only more likely to be 
effective, but also those that are more likely to be consequential for the animal S10. 
We defined a genomic cluster of miRNAs as a maximal segment such that every two 
consecutive miRNAs were separated by <50 kb. Genomic positions of miRNAs were taken 
from miRBase S2. 
Correlation analysis of the miRNA and mRNA expression profiles was performed by using 
the lists of differentially expressed miRNAs and mRNAs. The predicted mRNA targets of 
each of the dysregulated miRNAs were obtained using TargetScan 5.1. For a novel 
miRNA, only the predicted genes with conserved sites on the 3’ UTR were considered as 
targets. A two-tailed Fisher's Exact Test was performed to determine whether the number 
of target mRNAs that changed expression was greater than would be expected by chance. 
Fisher's Exact Test computed 107 unadjusted p-values from the dysregulated miRNAs that 
had predicted targets; all p-values were adjusted based on the Bonferroni method 
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accounting for multiple testing. P values less than 4.67E-04 (0.05 divided by 107) were 
considered to be significant.  
Pathway analysis based on the predicted target genes from all 42 down-regulated miRNA 
families, which had significantly inverse correlation with the expression of their target 
genes, was conducted using gene set enrichment analysis (GSEA) 
(http://www.broad.mit.edu/gsea/) S12. For purpose of comparison, we tested the same set 
of pathways as we used in our previous study S1 and defined overrepresented pathways by 
a NOM p-value ≤ 0.05 with a FDR ≤ 0.25. 
To test individual miRNA from 42 downregulated miRNA families possibly targeting 
multiple enriched pathways or multiple components of a pathway, we used a web-based 
tool – GENECODIS 2.0, which uses the hypergeometric distribution to determine whether 
individual pathway or combinations of pathways are significantly associated to a list of 
genes under study with respect to a reference list ( http://genecodis.genyo.es/) S13. The p 
values computed for each pathway were adjusted using the FDR method of Hochberg and 
Benjamini for multiple hypothesis testing, and corrected p values < 0.05 (-log2(p-value) 
>4.32) were considered significant.  
The experimentally validated miRNA-target pairs were obtained using the online 




Figure S1 Linear correlations between MKL and TKV or ht-TKV in validation 
cohort (A) where both measurements were available (n=19). (B) ROC analysis for MKL 
in predicting baseline eGFR (AUC 0.905) or discriminating eGFR slope (AUC 0.634).  
 
Figure S2 miRNA expression profiles of normal kidneys, MCTs and renal cysts 
based on the standardized signal intensities of (A) the top 500 most variable 
miRNAs and (B) 158 dysregulated miRNAs, derive a matrix of Pearson correlation 
coefficients that indicate the degree of overall similarity between any two samples. 
Positive correlation is indicated by red and negative correlation by green, with deeper 
colors indicating higher positive (red) or negative (green) correlations. Abbreviations: SC 
(small cysts); MC (medium cysts); LC (large cysts); MCT (minimally cystic tissue); 
KIDNEY (normal renal cortical tissue), and re (technical replicates). 
 
Figure S3 miRNA expression correlates with eGFR and mean kidney length. 
Significant correlations as determined by Spearman correlation coefficient calculations 
were observed between miRNA expression (dCT values) and (A) mean kidney length and 
(B) eGFR. 
 
Figure S4 ROC analysis of differentially expressed individual microRNAs to predict 
rapid disease progression in ADPKD. 
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ROC curves for the differentially expressed individual microRNAs to discriminate 
between patients with slow or rapid disease progression (annualized eGFR of < or > 
3ml/min/year over 5 years). A perfect diagnostic test has AUC of 1 while a value of 0.5 
indicates weak prediction ability. 
 
Figure S5 Knockdown of PIK3R1 or ANO1 confirmed by QPCR 
(A) Knockdown of PIK3R1 or ANO1 in the human cystic lines, OX161c1 or SKI-001 
respectively, measured by QPCR; (B) Uncropped blots of PI3K-p85a and PI3K-p110a 
following IGF-1 stimulation (see Figure 5B). 
 
Figure S6 Knockdown of PIK3R1 or chemical inhibition of PI3K inhibits IGF-1 
stimulated cyst growth 
 (A) OX161c1 cells were transfected with a negative control siRNA or PIK3R1 siRNA 
before being plated in 3D Matrigel and cultured in the presence or absence of IGF-1 
(200ng/ml) for 7 days. Knockdown of PIK3R1 abolished the IGF-1 response in 
transfected cells. Representative pictures of cysts for each condition indicate changes in 
cyst area after transfection. (B) OX161c1 cells grown in 3D Matrigel were treated with 
IGF-1 (200 ng/mL for 7 days). Control cells showed an increase in cyst area compared to 
untreated control cells (158% at 7 days). The PI3K inhibitor LY294002 at 20 μM or 50 
μM completely inhibited the response to IGF-1 treatment with significantly reduced cyst 
area (56% at day 7) compared to the untreated control condition. Scale bar: 20 μm. 






Supplementary Table 1. Differentially expressed miRNAs in human PKD1 renal cysts identified by SAM (FDR ≤ 0.1%) 
 
Dysregulated 





































hsa-let-7b↑ 13 1.2 1.4 H 
let-7/98 GAGGUAG 819 784 97↓ 2.0E-01 
hsa-let-7c↑ 25 1.6 1.9 H 
hsa-let-7d↑ 28 1.3 1.5 H 
hsa-let-7e↑ 81 1.2 1.3 H 
hsa-let-7f↑ 84 1.0 1.1 H 
hsa-let-7i↑ 12 1.1 1.5 H 
hsa-miR-23a↑ 38 1.2 1.5 H miR-23ab UCACAUU 838 801 108↓ 2.4E-02 




GGCAGUG 469 454 58↓ 2.2E-01 
hsa-miR-100↑ 59 1.2 1.4 H miR-99ab/100 ACCCGUA 40 39 6↓ 4.4E-01 
hsa-miR-125a-5p↑ 93 1.1 1.1 H 
miR-125/351 CCCUGAG 604 573 83↓ 8.1E-03 
hsa-miR-125b↑ 3 1.0 1.3 H 
hsa-miR-132↑ 81 1.2 1.8 H miR-132/212 AACAGUC 283 268 33↓ 4.9E-01 
hsa-miR-146a↑ 68 0.9 1.3 H miR-146 GAGAACU 130 123 13↓ 1.0E+00 
hsa-miR-152↑ 16 1.4 1.5 H miR-148/152 CAGUGCA 536 507 60↓ 5.2E-01 
hsa-miR-155↑ 97 1.1 2.2 H miR-155 UAAUGCU 281 266 31↓ 6.9E-01 
hsa-miR-196a 33 1.4 1.5 H miR-196ab AGGUAGU 211 199 27↓ 2.5E-01 
hsa-miR-214↑ 27 1.2 1.7 H miR-214/761 CAGCAGG 407 389 54↓ 7.1E-02 
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hsa-miR-221↑ 21 1.3 1.4 H 
miR-221/222 GCUACAU 307 293 34↓ 7.1E-01 




hsa-miR-9↓ 17 -4.2 -4.4 M miR-9 CUUUGGU 936 895 316↑ 1.6E-20 




AAAGUGC 990 935 337↑ 1.5E-23 
hsa-miR-20a↓ 98 -1.2 -1.2 H 
hsa-miR-20b↓ 58 -1.7 -2.5 H 
hsa-miR-106a↓ 91 -1.1 -1.3 H 
hsa-miR-106b↓ 73 -1.4 -1.6 H 
hsa-miR-18a↓ 44 -2.1 -2.7 M 
miR-18ab AAGGUGC 189 178 70↑ 2.3E-07 
hsa-miR-18b↓ 22 -2.0 -5.1 M 
hsa-miR-19a↓ 66 -1.9 -4.9 M 
miR-19 GUGCAAA 938 879 312↑ 1.1E-20 
hsa-miR-19b↓ 104 -1.2 -2.4 H 




GUAAACA 1080 1042 382↑ 2.7E-28 
hsa-miR-30b↓ 36 -1.3 -1.4 H 
hsa-miR-30c↓ 42 -1.2 -1.2 H 
hsa-miR-30d↓ 88 -1.1 -1.2 H 
hsa-miR-30e↓ 26 -1.4 -1.9 H 
hsa-miR-101↓ 76 -1.3 -1.8 H miR-101 ACAGUAC 607 578 199↑ 4.2E-12 
hsa-miR-107↓ 23 -1.5 -4.2 H miR-103/107 GCAGCAU 471 448 147↑ 4.5E-19 
hsa-miR-124↓ 15 -1.8 -13.4 M 
miR-124/506 AAGGCAC 1299 1253 436↑ 1.2E-26 
hsa-miR-506↓ 72 -4.7 -4.4 M 
hsa-miR-135a↓ 19 -1.9 -2.8 H 
miR-135 AUGGCUU 510 490 184↑ 3.2E-15 
hsa-miR-135b↓ 95 -2.6 -1.4 H 
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hsa-miR-138↓ 10 -2.1 -5.5 M miR-138 GCUGGUG 388 367 134↑ 2.0E-10 
hsa-miR-140-5p↓ 96 -1.5 -1.7 H miR-140/140-5p/876-
3p 
AGUGGUU 251 242 93↑ 7.3E-09 
hsa-miR-141↓ 46 -2.4 -3.5 H 
miR-141/200a AACACUG 531 504 198↑ 8.8E-19 
hsa-miR-200a↓ 92 -1.8 -2.0 H 
hsa-miR-142-3p↓ 52 -2.2 -1.8 H miR-142-3p GUAGUGU 250 242 92↑ 1.9E-08 
hsa-miR-144↓ 91 -0.7 -6.6 M miR-144 ACAGUAU 647 619 225↑ 2.0E-16 
hsa-miR-187↓ 2 -2.6 -8.3 M miR-187 CGUGUCU 4 2 1↑ 3.9E-01 
hsa-miR-190↓ 5 -2.5 -7.2 M miR-190 GAUAUGU 117 112 40↑ 8.5E-04 
hsa-miR-192↓ 4 -2.9 -4.7 H 
miR-192/215 UGACCUA 89 82 27↑ 2.3E-02 
hsa-miR-215↓ 8 -3.8 -9.1 M 
hsa-miR-194↓ 6 -2.8 -3.6 H miR-194 GUAACAG 258 248 89↑ 6.1E-07 
hsa-miR-204↓ 35 -1.9 -2.8 H miR-204/211 UCCCUUU 461 435 148↑ 7.6E-09 
hsa-miR-206↓ 99 -1.4 -2.4 M miR-1/206 GGAAUGU 584 557 197↑ 3.4E-13 
hsa-miR-216a↓ 72 -0.7 -2.3 M miR-216/216a AAUCUCA 161 153 37↑ 4.9E-01 
hsa-miR-217↓ 55 -0.9 -5.6 M miR-217 ACUGCAU 237 224 74↑ 1.3E-04 
hsa-miR-223↓ 56 -1.5 -1.0 H miR-223 GUCAGUU 202 189 70↑ 2.4E-06 
hsa-miR-301a↓ 36 -2.4 -4.5 H miR-130/301 AGUGCAA 724 684 229↑ 2.6E-12 
hsa-miR-338-3p↓ 23 -2.1 -3.3 H miR-338/338-3p CCAGCAU 198 191 69↑ 9.2E-06 
hsa-miR-455-5p↓ 37 -2.1 -3.4 M miR-455/455-5p AUGUGCC 135 129 48↑ 1.0E-04 
hsa-miR-503↓ 87 -1.4 -2.4 M miR-503 AGCAGCG 279 267 112↑ 2.8E-13 
hsa-miR-551b↓ 34 -1.9 -6.4 M miR-551ab CGACCCA 5 4 2↑ 2.1E-01 





hsa-miR-424↓ 21 -1.3 -1.5 H 
miR-
15/16/195/424/497 
hsa-miR-15b↑ 94 1.2 1.2 H 
968 924 117↓ 9.5E-02 
hsa-miR-195↑ 71 1.0 1.3 H 




692 661 66↓ 4.5E-01 
hsa-miR-363↓ 89 -1.5 -1.9 H 692 661 246↑ 2.4E-19 
Class 2↑ 
n=8 
hsa-miR-28-5p↑ 106 1.1 1.2 H miR-28/28-5p/708 AGGAGCU 111 100 17↓ 7.5E-02 
hsa-miR-134↑ 70 1.6 3.6 M miR-134 GUGACUG 96 92 7↓ 4.0E-01 
hsa-miR-197↑ 90 1.2 1.6 H miR-197 UCACCAC 140 134 18↓ 3.3E-01 
hsa-miR-224↑ 82 2.5 9.9 M miR-224 AAGUCAC 236 221 18↓ 1.9E-01 
hsa-miR-320abcd↑ 50 1.4 1.7 H miR-320/320abcd AAAGCUG 539 510 52↓ 6.2E-01 
hsa-miR-342-3p↑ 69 1.0 1.5 H miR-342/342-3p CUCACAC 169 156 21↓ 3.0E-01 
hsa-miR-361-5p↑ 47 1.1 1.2 H miR-361/361-5p UAUCAGA 138 130 19↓ 2.0E-01 




hsa-miR-340↓ 62 -2.1 -1.7 M miR-340/340-5p UAUAAAG 963 930 329↑ 2.3E-21 
hsa-miR-362-3p↓ 43 -2.1 -2.4 H miR-329/362-3p ACACACC 221 209 84↑ 3.6E-09 
hsa-miR-378↓ 40 -1.1 -2.0 H miR-378/422a CUGGACU 106 100 36↑ 1.5E-03 
hsa-miR-450a↓ 57 -1.8 -2.1 H miR-450a/450a-5p UUUGCGA 3 3 0↑ 1.0E+00 
hsa-miR-542-3p↓ 14 -2.6 -3.0 H miR-542/542-3p GUGACAG 156 153 46↑ 1.9E-02 
hsa-miR-708↓ 24 -1.6 -1.9 M miR-28/28-5p/708 AGGAGCU 111 100 27↑ 2.3E-01 




hsa-miR-28-3p↑ 105 1.1 1.3 H miR-28/28-3p ACUAGAU 77 72 8↓ 1.0E+00 
hsa-miR-151-3p↑ 39 1.2 1.4 H miR-151-3p UAGACUG 76 71 9↓ 5.7E-01 
hsa-miR-151-5p↑ 65 1.1 1.2 H miR-151 CGAGGAG 6 6 2↓ 1.3E-01 
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hsa-miR-193a-5p↑ 37 1.7 2.9 H miR-193a/193a-5p GGGUCUU 90 82 11↓ 4.8E-01 
hsa-miR-199a-3p↑ 
hsa-miR-199b-3p↑ 18 1.1 1.3 H miR-199/199-3p CAGUAGU 294 284 39↓ 1.5E-01 
hsa-miR-342-5p↑ 84 1.3 2.9 M miR-342-5p GGGGUGC 63 60 5↓ 6.8E-01 
hsa-miR-432↑ 83 2.8 5.6 M miR-432 CUUGGAG 133 126 19↓ 1.5E-01 
hsa-miR-452↑ 74 1.0 4.0 M miR-452.h ACUGUUU 205 199 19↓ 5.7E-01 




AAAGUAA 443 431 42↓ 4.4E-01 
hsa-miR-574-3p↑ 54 1.5 1.7 H miR-574/574-3p ACGCUCA 6 6 0↓ 1.0E+00 
hsa-miR-574-5p↑ 84 3.2 5.1 M miR-574-5p GAGUGUG 89 87 12↓ 3.9E-01 
hsa-miR-576-5p↑ 80 1.9 2.6 M miR-576-5p UUCUAAU 392 364 55↓ 1.4E-02 
hsa-miR-625↑ 101 1.4 2.3 M miR-625 GGGGGAA 70 67 7↓ 1.0E+00 
hsa-miR-628-3p↑ 53 1.8 1.8 M miR-628-3p CUAGUAA 71 67 7↓ 1.0E+00 
hsa-miR-628-5p↑ 99 2.5 2.4 M miR-628-5p UGCUGAC 157 152 18↓ 7.0E-01 
hsa-miR-664↑ 98 1.1 1.3 H miR-664.hr AUUCAUU 406 386 55↓ 4.8E-02 
hsa-miR-923↑ 91 4.9 5.5 H miR-923 UCAGCGG 3 3 0↓ 1.0E+00 
hsa-miR-1246↑ 103 1.5 2.2 H miR-1246 AUGGAUU 114 106 7↓ 2.1E-01 




hsa-miR-129-3p↓ 29 -4.8 -2.3 M miR-129-3p AGCCCUU 286 274 94↑ 3.1E-06 
hsa-miR-142-5p↓ 70 -3.4 -4.0 M miR-142-5p AUAAAGU 537 520 191↑ 1.3E-14 
hsa-miR-188-5p↓ 9 -1.8 -3.8 M miR-188/188-5p AUCCCUU 152 141 42↑ 3.2E-02 
hsa-miR-337-5p↓ 80 -2.3 -2.8 M miR-337-5p.h AACGGCU 13 13 3↑ 1.0E+00 
hsa-miR-339-3p↓ 48 -1.7 -2.3 M miR-339-3p GAGCGCC 11 11 5↑ 7.3E-02 
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hsa-miR-362-5p↓ 28 -2.1 -3.4 M miR-362-5p AUCCUUG 93 89 31↑ 6.6E-03 
hsa-miR-450b-5p↓ 47 -2.0 -2.1 M miR-450b/450b-5p UUUGCAA 510 484 195↑ 8.2E-20 
hsa-miR-500↓ 32 -1.8 -2.1 H miR-500.h AAUCCUU 179 167 65↑ 7.5E-07 
hsa-miR-501-3p↓ 73 -1.5 -1.7 M miR-500/501-
3p/502/502-3p 
AUGCACC 151 145 57↑ 2.6E-06 
hsa-miR-501-5p↓ 74 -1.9 -2.2 M miR-501/501-5p AUCCUUU 150 145 56↑ 6.9E-06 
hsa-miR-507↓ 41 -1.2 -3.0 M miR-507/557 UUUGCAC 343 323 127↑ 2.2E-12 
hsa-miR-508-3p↓ 43 -5.5 -5.2 M miR-508-3p GAUUGUA 218 210 75↑ 5.2E-06 
hsa-miR-509-3-5p↓ 43 -12.4 -12.7 M miR-509-5p/509-3-5p ACUGCAG 265 247 88↑ 9.1E-07 
hsa-miR-509-3p↓ 31 -9.1 -7.2 M miR-509-3p.h GAUUGGU 87 82 24↑ 1.4E-01 
hsa-miR-513a-3p↓ 60 -4.9 -4.3 M miR-513a-3p AAAUUUC 468 453 155↑ 1.9E-09 
hsa-miR-514↓ 7 -13.0 -14.6 H miR-514 UUGACAC 190 178 61↑ 1.7E-04 
hsa-miR-532-5p↓ 89 -1.3 -1.4 H miR-532/532-5p AUGCCUU 130 125 42↑ 3.2E-03 
hsa-miR-542-5p↓ 41 -1.6 -3.5 M miR-542-5p.h CGGGGAU 3 3 1↑ 5.3E-01 
hsa-miR-582-5p↓ 94 -1.8 -2.4 M miR-582-5p.h UACAGUU 484 463 178↑ 7.4E-16 
hsa-miR-618↓ 51 -1.3 -2.3 M miR-618 AACUCUA 123 117 48↑ 4.9E-06 
hsa-miR-660↓ 107 -1.9 -1.9 M miR-660 ACCCAUU 89 85 23↑ 2.9E-01 
hsa-miR-720↓ 20 -1.3 -1.6 H miR-720.h CUCGCUG 5 5 0↑ 1.0E+00 
hsa-miR-876-3p↓ 54 -1.7 -4.7 M miR-876-3p GGUGGUU 93 89 31↑ 6.6E-03 
hsa-miR-888↓ 36 -1.1 -8.1 M miR-888 ACUCAAA 235 221 80↑ 1.7E-06 
hsa-miR-891a↓ 80 -0.7 -4.5 M miR-891a GCAACGA 4 4 1↑ 1.0E+00 
hsa-miR-1201↓ 106 -1.1 -1.2 H miR-1201 GCCUGAU  92 88 38↑ 1.3E-05 
hsa-miR-1274b↓ 91 -1.2 -1.3 H miR-1274b CCCUGUU 128 120 36↑ 4.6E-02 
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hsa-miR-1307↓ 61 -1.9 -2.0 M miR-1307 CUCGGCG 3 3 2↑ 1.2E-01 





hsa-miR-9*↓ 88 -2.1 -2.1 M     N/A       
hsa-miR-16-1*↓ 46 -2.2 -2.5 M   N/A    
hsa-miR-20a*↓ 63 -1.7 -2.4 M   N/A    
hsa-miR-24-1*↓ 38 -2.3 -4.0 M   N/A    
hsa-miR-29a*↓ 30 -2.0 -2.7 H   N/A    
hsa-miR-29c*↓ 95 -1.1 -1.4 H   N/A    
hsa-miR-30c-2*↓ 100 -1.3 -1.6 M   N/A    
hsa-miR-30d*↓ 11 -1.7 -3.8 M   N/A    
hsa-miR-129*↓ 15 -4.5 -4.2 M   N/A    
hsa-miR-132*↓ 92 -1.9 -1.4 M   N/A    
hsa-miR-154*↓ 86 -2.2 -2.4 M   N/A    
hsa-miR-181a*↓ 98 -1.5 -1.5 M   N/A    
hsa-miR-192*↓ 1 -9.7 -32.2 M   N/A    
hsa-miR-194*↓ 45 -1.2 -2.0 M   N/A    
hsa-miR-378*↓ 71 -1.0 -2.5 M   N/A    
hsa-miR-424*↓ 91 -1.5 -2.1 M   N/A    
HS_100↓ 83 -1.1 -1.7 H   N/A    
HS_97↓ 93 -1.1 -2.2 M   N/A    
HS_108.1↑ 79 2.4 3.4 M   N/A    
HS_204.1↑ 49 1.2 1.2 H   N/A    
HS_244↑ 98 1.4 1.5 M   N/A    
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hsa-let-7d*↑ 60 1.5 1.7 H   N/A    
hsa-miR-10a*↑ 67 1.2 1.4 M   N/A    
hsa-miR-199a*:9.1↑ 29 1.2 1.4 H   N/A    
hsa-miR-23b*↑ 96 2.1 2.3 M   N/A    
hsa-miR-493*↑ 75 1.6 2.8 M   N/A    
hsa-miR-664*↑ 78 2.4 3.1 M   N/A    
solexa-9029-92↑ 102 1.2 1.2 M     N/A       
 
TargetScan classifies miRNAs into families based on identical seed region 
     
Class 1: broadly conserved miRNA family across most vertebrates, usually to zebrafish      
Class 2: conserved miRNA family across most mammals, but usually not beyond placental mammals      
Class 3: poorly conserved miRNA family      
Kidney enriched miRNAs are in bold and italic         
# According to the average expression level of miRNAs in any of 3 renal groups, dysregulated miRNAs were either highly expressed (H): signal intensity between 10000 – 40000, or moderately 
expressed (M): signal intensity between 1000 – 10000 
##For a novel miRNA, only the conserved predicted targets were considered as targets      
^A two-tailed Fisher’s Exact Test was used to determine if the number of predicted target genes that actually changed expression in PKD1 renal cysts was greater than would be expected by 
chance. All p-values were adjusted based on the Bonferroni method accounting for multiple testing. p < 4.67E-04 (0.05/107)  were considered as significance 
Dysregulated miRNA/mRNA: Up (↑) and Down (↓) in PKD1 renal cysts vs. MCT and normal kidney samples     
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Chromosome Dysregulated miRNAs##             
mir-30e (2) 1p34.2 miR-30c↓ miR-30e↓       
mir-215-194-1 (2) 1q42.1 miR-194↓ miR-215↓       
mir-216a (3) 2p16.1 miR-216a↓ miR-217↓       
mir-30a (2) 6q13 miR-30a↓ miR-30c↓ miR-30c-2*↓      
mir-30b (2) 8q24.22 miR-30b↓ miR-30d↓ miR-30d*↓      
mir-194-2-192 (2) 11q13.1 miR-192↓ miR-192*↓ miR-194↓ miR-194*↓     
mir-15a (2) 13q14.2 miR-15a↓ miR-16-1*↓       
mir-17-92 (6) 13q31.3 miR-17↓ miR-18a↓ miR-19a↓ miR-20a↓ miR-20a*↓ miR-19b↓   
mir-188 (7) Xp11.23 miR-532-5p↓ miR-188-5p↓ miR-660↓ miR-362-3p↓ miR-362-5p↓ miR-500↓ miR-501-3p↓ 
miR-501-
5p↓ 
mir-424 (6) Xq26.3 miR-424↓ miR-424*↓ miR-503↓ miR-542-3p↓ miR-542-5p↓ miR-450a↓ miR-450b-5p↓  
mir-106a-363 (6) Xq26.2 miR-106a↓ miR-18b↓ miR-20b↓ miR-19b↓ miR-363↓    




miR-514↓ miR-509-3-5p↓ miR-509-3p↓ miR-508-3p↓ miR-507↓ miR-506↓ miR-513a-3p↓  
mir-199a-1 (3) 1q24.3 miR-214↑ miR-199a-3p↑       
let-7d (3) 9q22.32 let-7d↑ let-7d*↑ let-7f↑      
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mir-100 (3) 11q24.1 miR-100↑ miR-125b↑       
mir-99b (3) 19q13.41 let-7e↑ miR-125a-5p↑       
mir-221 (2) Xp11.3 miR-221↑ miR-222↑       
mir-224 (2) Xq28 miR-224↑ miR-452↑       
mir-106b-25 (3) 7q22.1 miR-106b↓ miR-25↑       
mir-23b (3) 9q22.32 miR-24-1*↓ miR-23b*↑       
mir-127 (10) 14q32.2 miR-337-5p↓ miR-493*↑ miR-432↑      
mir-134 (41) 14q32.31 miR-154*↓ miR-134↑ miR-379↑           
 
# The numbers in brackets are the total numbers of miRNA genes within a proximal 50kb distance on a chromosome 
  








Supplementary Table 3 Linear regression analysis for selected clinical and biochemical 
variables identifying independent associations with differentially expressed microRNAs. 
Standardized β (standardized coefficients beta) denotes that an alteration of 1SD in the clinical 
parameters (independent variable) will lead to a one measurement change in the corresponding 



















Age (year) 0.128 (0.338) 0.133 (0.4) 0.133 (0.318) 0.091 (0.498) 0.164 (0.218) 
BMI (kg/m
2





-0.577 (0.00) -0.444 (0.002) -0.550 (0.00) -0.495 (0.00) -0.288 (0.055) 
eGFR slope 
(ml/min/year) 
-0.415 (0.01) -0.275 (0.085) -0.399 (0.01) -0.369 (0.01) -0.234 (0.146) 
MKL (cm) 0.432 (0.01) 0.232 (0.154) 0.436 (0.006) 0.533 (0.000) 0.294 (0.069) 
Cholesterol 
(mmol/l) 
-0.186 (0.162) -0.190 (0.15) -0.222 (0.09) -0.157 (0.24) -0.066 (0.621) 
Uric acid (µmol/l) 0.103 (0.464) 0.466 (0.000) 0.137 (0.328) 0.027 (0.846) 0.123 (0.328) 
PTH (mmol/l) 0.362 (0.036) 0.120 (0.499) 0.301 (0.084) 0.322 (0.064) -0.032 (0.859) 
PCR (mg/mmol) 0.358 (0.057) 0.289 (0.128) 0.372 (0.047) 0.458 (0.013) 0.192 (0.317) 
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Supplementary Table 4 Pathway analysis using DAVID based on changes in the five 



















Wnt signaling 0.02 (1.5) 0.01 (1.5) 0.02(1.5) ns 4.45E-04 (2) 
MAPK 
signaling 0.02 (1.3) 0.03 (1.3) 0.01 (1.4) 0.04 (1.5) ns 
ErbB signaling 0.02 (1.7) 0.01 (1.8) 0.007 (1.8) ns ns 
Calcium 
signaling 0.04 (1.4) 0.04 (1.4) 0.03 (1.4) ns ns 
Apoptosis 0.003(1.98) 0.006 (1.9) 0.01 (1.7) 0.01 (2.3) ns 
p53 signaling ns ns 0.03 (1.7) ns ns 
Cell cycle ns ns ns 0.03 (1.9) ns 
Endocytosis ns ns ns ns 0.002 ( 1.7) 
Focal adhesion ns ns ns ns 0.01 (1.5) 
JAK-STAT 
signaling ns ns ns ns 0.02 (1.6) 
mTOR 




Supplementary Table 5. Selected down-regulated miRNAs in human PKD1 renal cysts 
identified by SAM (FDR <0.1%), whose expression were also inversely correlated with the 






















hsa-miR-9 CUUUGGU 17 -4.2 -4.4 M 1.6E-20 
hsa-miR-15a 
AGCAGCA 
102 -1.2 -1.2 H 
8.8E-21 
hsa-miR-424 21 -1.3 -1.5 H 
hsa-miR-17 
AAAGUGC 
77 -1.1 -1.3 H 
1.5E-23 
hsa-miR-20a 98 -1.2 -1.2 H 
hsa-miR-20b 58 -1.7 -2.5 H 
hsa-miR-106a 91 -1.1 -1.3 H 
hsa-miR-106b 73 -1.4 -1.6 H 
hsa-miR-18a 
AAGGUGC 
44 -2.1 -2.7 M 
2.3E-07 
hsa-miR-18b 22 -2.0 -5.1 M 
hsa-miR-19a 
GUGCAAA 
66 -1.9 -4.9 M 
1.1E-20 
hsa-miR-19b 104 -1.2 -2.4 H 
hsa-miR-30a 
GUAAACA 
57 -1.4 -1.4 H 
2.7E-28 
hsa-miR-30b 36 -1.3 -1.4 H 
hsa-miR-30c 42 -1.2 -1.2 H 
hsa-miR-30d 88 -1.1 -1.2 H 
hsa-miR-30e 26 -1.4 -1.9 H 
hsa-miR-101 ACAGUAC 76 -1.3 -1.8 H 4.2E-12 
hsa-miR-107 GCAGCAU 23 -1.5 -4.2 H 4.5E-19 
hsa-miR-124 
AAGGCAC 
15 -1.8 -13.4 M 
1.2E-26 
hsa-miR-506 72 -4.7 -4.4 M 
hsa-miR-135a 
AUGGCUU 
19 -1.9 -2.8 H 
3.2E-15 
hsa-miR-135b 95 -2.6 -1.4 H 
hsa-miR-138 GCUGGUG 10 -2.1 -5.5 M 2.0E-10 
hsa-miR-140-5p AGUGGUU 96 -1.5 -1.7 H 7.3E-09 
hsa-miR-141 
AACACUG 
46 -2.4 -3.5 H 
8.8E-19 
hsa-miR-200a 92 -1.8 -2.0 H 
hsa-miR-142-3p GUAGUGU 52 -2.2 -1.8 H 1.9E-08 
hsa-miR-144 ACAGUAU 91 0.7 -6.6 M 2.0E-16 
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hsa-miR-194 GUAACAG 6 -2.8 -3.6 H 6.1E-07 
hsa-miR-204 UCCCUUU 35 -1.9 -2.8 H 7.6E-09 
hsa-miR-206 GGAAUGU 99 -1.4 -2.4 M 3.4E-13 
hsa-miR-217 ACUGCAU 55 0.9 -5.6 M 1.3E-04 
hsa-miR-223 GUCAGUU 56 -1.5 1.0 H 2.4E-06 
hsa-miR-301a AGUGCAA 36 -2.4 -4.5 H 2.6E-12 
hsa-miR-338-3p CCAGCAU 23 -2.1 -3.3 H 9.2E-06 
hsa-miR-363 AUUGCAC 89 -1.5 -1.9 H 2.4E-19 
hsa-miR-455-5p AUGUGCC 37 -2.1 -3.4 M 1.0E-04 
hsa-miR-503 AGCAGCG 87 -1.4 -2.4 M 2.8E-13 
Class 2 
(n=2) 
hsa-miR-340 UAUAAAG 62 -2.1 -1.7 M 2.3E-21 
hsa-miR-362-3p ACACACC 43 -2.1 -2.4 H 3.6E-09 
Class 3 
(n=15) 
hsa-miR-129-3p AGCCCUU 29 -4.8 -2.3 M 3.1E-06 
hsa-miR-142-5p AUAAAGU 70 -3.4 -4.0 M 1.3E-14 
hsa-miR-450b-5p UUUGCAA 47 -2.0 -2.1 M 8.2E-20 
hsa-miR-500 AAUCCUU 32 -1.8 -2.1 H 7.5E-07 
hsa-miR-501-3p AUGCACC 73 -1.5 -1.7 M 2.6E-06 
hsa-miR-501-5p AUCCUUU 74 -1.9 -2.2 M 6.9E-06 
hsa-miR-507 UUUGCAC 41 -1.2 -3.0 M 2.2E-12 
hsa-miR-508-3p GAUUGUA 43 -5.5 -5.2 M 5.2E-06 
hsa-miR-509-3-5p ACUGCAG 43 -12.4 -12.7 M 9.1E-07 
hsa-miR-513a-3p AAAUUUC 60 -4.9 -4.3 M 1.9E-09 
hsa-miR-514 UUGACAC 7 -13.0 -14.6 H 1.7E-04 
hsa-miR-582-5p UACAGUU 94 -1.8 -2.4 M 7.4E-16 
hsa-miR-618 AACUCUA 51 -1.3 -2.3 M 4.9E-06 
hsa-miR-888 ACUCAAA 36 -1.1 -8.1 M 1.7E-06 
hsa-miR-1201 GCCUGAU  106 -1.1 -1.2 H 1.3E-05 
TargetScan classifies miRNAs into families based on identical seed region; for a novel miRNA, only the conserved 
predicted target genes were considered as targets. 
Class 1: broadly conserved miRNA family across most vertebrates, usually to zebrafish 
Class 2: conserved miRNA family across most mammals, but usually not beyond placental mammals 
Class 3: poorly conserved miRNA family 
# highly expressed (H): signal intensity 10000 – 40000, moderately expressed (M): 1000 – 10000. 
^ A Fisher’s Exact Test was used to determine if the number of predicted target genes that actually changed expression in 
PKD1 renal cysts was greater than would be expected by chance. All p-values were adjusted based on the Bonferroni 
method accounting for multiple testing; p < 4.67E-04 (0.05/107) were considered as significance. 
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Supplementary Table 6. Pathways predicted to be affected by 42 downregulated miRNA 
families as identified by GSEA at NOM p ≤ 0.05 and FDR ≤ 0.25 







Proliferation (1)     
   SMITH_HTERT_UP* 1.65 0.011 0.182 16 
Mitogenic signaling pathways via RTKs (7)     
   IGF1_NIH3T3_UP* 1.76 0.005 0.113 9 
   MAPKPATHWAY* 1.58 0.011 0.217 27 
   HDACPATHWAY* 1.57 0.023 0.208 28 
   ST_JNK_MAPK_PATHWAY* 1.53 0.024 0.220 37 
   SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES* 1.47 0.037 0.221 48 
   FCER1PATHWAY* 1.49 0.050 0.243 43 
   NGFPATHWAY* 1.54 0.042 0.241 31 
Cell cycle (6)     
   IGLESIAS_E2FMINUS_UP* 1.82 <0.001 0.095 5 
   LEE_E2F1_UP* 1.70 0.007 0.129 13 
   RACCYCDPATHWAY* 1.68 0.012 0.148 15 
   HSA04110_CELL_CYCLE* 1.58 0.017 0.220 25 
   VERNELL_PRB_CLSTR1* 1.55 0.022 0.237 30 
   G1PATHWAY 1.53 0.046 0.224 34 
Wnt pathway (3)     
   WNT DIRECT TARGETS* 1.69 0.014 0.141 14 
   ST_WNT_BETA_CATENIN_PATHWAY* 1.61 0.024 0.212 20 
   WNT_SIGNALING* 1.47 0.038 0.224 47 
Notch pathway (2)     
   NGUYEN_KERATO_DN* 1.47 0.036 0.225 46 
   HSA04330_NOTCH_SIGNALING_PATHWAY* 1.58 0.030 0.227 24 
BMP/TGFβ/Activin pathway (5)     
   TGFBETA_ALL_UP* 1.78 0.004 0.113 7 
   TGFBETA_EARLY_UP* 1.96 <0.001 0.038 2 
   HSA04350_TGF_BETA_SIGNALING_PATHWAY* 1.72 <0.001 0.122 12 
   ALKPATHWAY* 1.56 0.042 0.217 29 
   TGFBETA_C1_UP* 1.52 0.043 0.219 39 
Epithelial-mesenchymal transition (2)     
   EMT_UP* 1.98 <0.001 0.041 1 
   JECHLINGER_EMT_UP* 1.93 <0.001 0.040 3 
Hypoxia pathway (3)     
 29 
   HYPOXIA_REVIEW* 1.63 0.009 0.205 17 
   HIFPATHWAY* 1.48 0.047 0.223 45 
   HYPOXIA_FIBRO_UP* 1.61 0.023 0.202 21 
Aging (1)     
   AGEING_KIDNEY_SPECIFIC_UP* 1.75 <0.001 0.117 10 
Ca2+ mediated signaling pathway (3)     
   NDKDYNAMINPATHWAY* 1.50 0.046 0.232 41 
   CALCINEURINPATHWAY* 1.73 0.005 0.122 11 
   NFATPATHWAY* 1.42 0.042 0.243 50 
Genomic integrity (1)     
   PARP_KO_UP* 1.60 0.015 0.205 23 
Cytokine mediated JAK-STAT, MEK/ERK cascades (4)    
   IL2RBPATHWAY* 1.63 0.017 0.202 18 
   TPOPATHWAY* 1.61 0.013 0.216 19 
   GHPATHWAY* 1.49 0.042 0.245 42 
   IL2PATHWAY 1.52 0.045 0.222 38 
MYC regulated genes (1)     
   LEE_MYC_UP* 1.53 0.041 0.215 36 
Immune and inflammatory response (2)     
   PAR1PATHWAY* 1.54 0.042 0.235 32 
   NTHIPATHWAY* 1.49 0.047 0.236 44 
p53 pathway (1)     
   P53GENES_ALL* 1.77 0.004 0.112 8 
Oxidative damage (1)     
   ARENRF2PATHWAY* 1.86 0.003 0.068 4 
Differentiation (1)     
   ETSPATHWAY* 1.54 0.032 0.231 33 
Nuclear receptor signaling (4)     
   GCRPATHWAY* 1.58 0.018 0.212 26 
   CARM_ERPATHWAY* 1.60 0.020 0.204 22 
   BREAST_CANCER_ESTROGEN_SIGNALING* 1.44 0.038 0.229 49 
   RARRXRPATHWAY* 1.51 0.048 0.232 40 
Wilms' tumor signature (1)     
   LI_FETAL_VS_WT_KIDNEY_DN* 1.81 <0.001 0.092 6 
Cell communication (1)     
   HSA01430_CELL_COMMUNICATION 1.53 0.025 0.220 35 
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U n tra n s fe c te d
    (c o n tro l)
N e g a tiv e
 s iR N A
P IK 3 R 1
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1 0 0 0
IG F -1
* * ** * * **
c o n tro l L Y 2 9 0 0 4
 20  M
L Y 2 9 0 0 4
 50  M
